UBX Unity Biotechnology Inc.

8.3
-0.27  -3%
Previous Close 8.57
Open 8.55
Price To Book 2.43
Market Cap 356,129,337
Shares 42,907,149
Volume 253,045
Short Ratio
Av. Daily Volume 281,690

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data released June 18, 2019. Mixed efficacy data.
UBX0101
Osteoarthritis

Latest News

  1. UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
  2. The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug
  3. UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline
  4. UNITY Biotechnology, Inc. to Present at Upcoming Investor Conferences
  5. The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
  6. 5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
  7. Do Directors Own Unity Biotechnology, Inc. (NASDAQ:UBX) Shares?
  8. UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results
  9. UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results
  10. UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates
  11. UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference
  12. CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
  13. UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
  14. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
  15. UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee
  16. Ascentage Pharma Announces New License with Unity Biotechnology
  17. UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye
  18. This year's Bay Area IPO batch remains up 44% despite market turbulence
  19. UNITY (UBX) Soars: Stock Adds 5.1% in Session
  20. UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors